Katalyze AI Launches Digityze AI on Snowflake AI Data Cloud, Enabling GMP-Ready Intelligence for Biomanufacturing
Available on Snowflake Marketplace, Digityze AI combines advanced machine learning, biophysics-informed models, and visual AI to organize complex manufacturing documents, including PDFs, handwritten notes, tables, forms, and fragmented data, unlocking critical insights.
Built for biopharmaceutical and other highly-regulated industries, Digityze AI is an integration of generative AI, raw material characterization, and large language models that automates the extraction, validation and approval of data buried in complex documents such as Certificates of Analysis (CoAs), batch records, SOPs, lab reports and any other document type specific to the organization's needs. With modular workflows and support for human oversight, the platform enables teams to achieve both high accuracy and auditability.
'Pharmaceutical manufacturers are under immense pressure to streamline their processes, reduce waste and improve output, all while maintaining stringent regulatory compliance,' said Reza Farahani, CEO, Katalyze AI. 'By launching Digityze AI on Snowflake, we're making it easy for life science companies to extract critical data from buried documents and put it to use across their AI workflows, securely, at scale and in real time.'
'Katalyze AI's commitment to helping Snowflake empower every enterprise to achieve its full potential through data and AI can be seen through the launch of Digityze AI,' said Shannon Katschilo, Country Manager of Canada, Snowflake. 'We look forward to driving deeper value for Snowflake's AI Data Cloud ecosystem by delivering enhanced value to customers in highly-regulated industries through streamlined data insights, rapid analytics capabilities, and enterprise-scale AI solutions.'
Building Digityze AI as a Snowflake Native App enables customers to deploy and operate the service directly within their own Snowflake environments. This helps ensure secure, governed and seamless integration with existing data pipelines, eliminates data silos and unlocks end-to-end process visibility. To learn more visit katalyzeai.com.
Read the blog: Katalyze AI Revolutionizes Biomanufacturing with Document Intelligence
About Katalyze AI
Katalyze AI provides an AI-driven biomanufacturing platform designed to support biotech and pharmaceutical manufacturers in analyzing raw materials, optimizing production processes, and enhancing operational efficiency. By focusing on yield improvement, quality consistency, and demand reliability, Katalyze AI addresses key challenges in biomanufacturing to support reliable, data-informed production outcomes. The platform is built to integrate seamlessly into existing workflows, enabling manufacturers to make informed decisions and drive sustainable growth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 hours ago
- Malaysian Reserve
U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer
Orphan drug designation highlights the potential for ADRX-0405 to address the high unmet need in gastric cancer SAN DIEGO, July 8, 2025 /PRNewswire/ — Adcentrx Therapeutics ('Adcentrx'), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ADRX-0405, for the treatment of patients with gastric cancer. ADRX-0405 is a STEAP1 ADC being evaluated in the Phase 1a portion of an ongoing Phase 1a/b clinical trial (NCT06710379) for the treatment of select advanced solid tumors, including metastatic castration resistant prostate cancer, gastric cancer, and non-small cell lung cancer. While STEAP1 is primarily associated with prostate cancer, there is a meaningful amount of target expression in gastric cancer, making this a potential indication of interest for future clinical development. 'Receiving orphan drug designation from FDA is a notable milestone for Adcentrx and reinforces the potential for ADRX-0405 to improve the lives of patients with gastric cancer,' said Hui Li, Ph.D., Founder and Chief Executive Officer of Adcentrx. 'We are encouraged by the progress of our Phase 1a trial and look forward to further evaluating the safety, tolerability and anti-tumor activity of ADRX-0405 in gastric and other cancers.' Gastric cancer, or stomach cancer, is a serious malignancy that develops in the stomach lining and is often diagnosed at advanced stages. The American Cancer Society estimates there will be 30,300 new cases of gastric cancer in the U.S. in 2025, meeting FDA's criteria for a rare disease. The orphan drug designation is a program designed to stimulate the development of treatments for rare diseases, defined as conditions affecting fewer than 200,000 people in the U.S. Benefits of this designation include access to grant funding and scientific assistance, tax credits for qualified clinical trials, waiver of Prescription Drug User Fee Act (PDUFA) application fees, and the potential for seven years of market exclusivity following regulatory approval. About ADRX-0405ADRX-0405 is a clinical-stage next-generation ADC targeting six-transmembrane epithelial antigen of the prostate 1 (STEAP1), a cell surface protein that is upregulated in prostate cancer and certain other cancers with limited expression in normal healthy tissue. The ADC is composed of a humanized IgG1 antibody coupled with a novel topoisomerase inhibitor linker-payload through Adcentrx's innovative i-Conjugation® technology platform – a core component in the design of the company's ADCs. The platform utilizes a cleavable linker and stable conjugation chemistry to enhance payload delivery. This novel technology enables a highly stable ADC with a drug-antibody ratio of eight (DAR 8) to maximize payload delivery to solid tumors. ADRX-0405 preclinical studies have demonstrated its favorable pharmacokinetics, safety profile, and significant efficacy across multiple animal tumor models. ADRX-0405 is currently being evaluated in a Phase 1a/b clinical trial. For more information about the ADRX-0405 Phase 1a/b clinical trial, please refer to the Study ID NCT06710379 on About Adcentrx TherapeuticsAdcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. Adcentrx has pioneered the development of an ADC technology platform addressing key components of protein conjugate design to solve challenges typically seen in ADCs. Adcentrx is developing a robust pipeline including two clinical-stage ADCs and multiple preclinical ADCs, all with first-in-class and best-in-class potential. For more information about Adcentrx and its innovative ADC technologies, please visit Contact Information:Investor Relationsir@
Malaysian Reserve
5 hours ago
- Malaysian Reserve
CENTERSPACE ANNOUNCES SECOND QUARTER 2025 EARNINGS RELEASE DATE
MINNEAPOLIS, July 8, 2025 /PRNewswire/ — Centerspace (NYSE: CSR) will release its operating results for the quarter ended June 30, 2025, after the market closes on Monday, August 4, 2025. Management will host a conference call to discuss those results on Tuesday, August 5, 2025, at 10:00 a.m. Eastern Time. Interested parties may access the conference call via the following: Live Conference Call Details: Live webcast: Operator Assisted Dial-In:United States (Local): +1 404 975 4839United States (Toll-Free): +1 833 470 1428Canada: +1 226 828 7575Canada (Toll-Free): +1 833 950 0062Access Code: 547256 Replay Details: Replay Expiration Date: Tuesday, August 12, 2025 11:59 PM EDT Replay Dial-In:United States (Local): +1 929 458 6194United States (Toll-Free): +1 866 813 9403Access Code: 134183 About Centerspace Centerspace is an owner and operator of apartment communities committed to providing great homes by focusing on integrity and serving others. Founded in 1970, the company currently owns 72 apartment communities consisting of 13,353 homes located in Colorado, Minnesota, Montana, Nebraska, North Dakota, South Dakota, and Utah. Centerspace was named a top workplace for the sixth consecutive year in 2025 by the Minneapolis Star Tribune. For more information, please visit If you would like more information about this topic, please contact Josh Klaetsch, Investor Relations, at (952) 401-6600 or IR@ Contact Information Josh Klaetsch, Investor Relations Phone : (952) 401-6600 E-mail : IR@
Malaysian Reserve
6 hours ago
- Malaysian Reserve
Collective Project Launches Bold New Portfolio of Hemp-Derived THC Beverages in the U.S.
Top selling Canadian cannabis beverage brand known for creative collaborations and flavor-forward beverages now shipping direct-to-consumer across the country NEW YORK, July 8, 2025 /PRNewswire/ — Collective Project, the Canadian cannabis beverage brand known for its bold flavor pairings, real fruit juices, and creative can design collaborations with emerging artists, has officially launched in the U.S. with direct-to-consumer shipping in 25 states.* This major milestone follows Collective Project's acquisition earlier this year by Organigram Global, Canada's #1 cannabis company by market share. After a soft launch of its sparkling juice lineup in select states in Fall 2024, Collective Project built early excitement for its flavorful, fruit-forward beverages. The brand now expands to consumers across the country with full-scale e-commerce and the debut of its new sparkling lemonades – all crafted with real fruit juice, high-quality ingredients, and hemp-derived THC. At Collective Project, every can is a canvas. Every beverage is a collaboration between the brand's flavor creators and visual artists from around the world, transforming every product into a functional piece of art. Through this global creative platform, Collective Project brings together expressive design, great taste, and a modern way to enjoy cannabis. 'Collective Project is rooted in flavor and creativity,' said Megan McCrae, SVP, Corporate Strategy & International Growth, Organigram Global. 'We're proud to partner with artists from around the world to create cans that reflect the vibrant community behind our brand. And as the hemp-derived Delta-9 space grows, we see a real opportunity to offer consumers a modern, social alternative to alcohol – one that brings together great taste, thoughtful ingredients, and artistic expression.' Sparkling JuicesThe sparkling juice lineup offers rich, effervescent flavors made with true-to-fruit blends for an unmatched full-body experience. Currently available in 4-packs (12oz cans): Blood Orange, Yuzu & Vanilla (available in 5mg and 10mg THC) Mango, Pineapple & Coconut (available in 5mg and 10mg THC) Raspberry Vanilla (available in 10mg THC) New: Sparkling LemonadesThe sparkling lemonades offer a zesty, low-calorie, and low-sugar option that adds a bubbly twist to every celebration. Available in 4-packs (12oz cans): Classic Lemonade (available in 5mg THC) Raspberry Lemonade (available in 5mg THC) Cherry Limeade (available in 5mg THC) All beverages are made with high quality hemp-derived THC and are tested by independent third parties for consistency, quality, and compliance. With a variety of THC levels, there's a dose for every kind of cannabis experience and lifestyle. Collective Project products are available for purchase by consumers 21+. Collective Project is available online at for shipping directly to many states and at select retailers including Total Wine (IN, MN, NC, SC) and Top Ten (MN). The brand will also introduce Fetch, a new line of bold hemp-derived THC sodas, later this summer, with full details to be announced closer to launch. To place an order, explore the full lineup, or meet the artists behind the cans, visit and follow @drinkcollectiveproject on Instagram. *Collective Project is now shipping to Arkansas, Delaware, Florida, Georgia, Illinois, Indiana, Kansas, Maine, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Wisconsin, and Wyoming. ABOUT COLLECTIVE PROJECTCollective Project is a Canadian cannabis and U.S. hemp beverage brand. Collective Project believes that a creative world is a better world and we're on a mission to bring inspiration, collaboration, and creativity into everyday life. Our hemp-derived THC beverages are made with real fruit juice, clean ingredients, and balanced dosing, offering a bold, flavorful way to enjoy hemp-derived products. More than a drink, each can is a collaboration between flavor creators and visual artists, turning everyday moments into something expressive, social, and a little more inspired. ABOUT ORGANIGRAMOrganigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project Limited, Organigram Global participates in the U.S. and Canadian cannabinoid beverage markets through the sale of the Collective Project and Fetch THC beverage brands. Media Contact: collectiveproject@
